Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a widespread diagnosis that affects many children and adolescents’ ability to function and succeed in academics, socially, or other situations. Non-stimulant medications have become widely utilized in this population, especially in stimulant-resistant individuals, whether due to poor efficacy or intolerance of side effects. However, these, too, harbor their own side effect profiles, including cardiovascular and sleep or energy level disturbances.
Objectives: We review the literature in discussion of the presentation and management of these adverse events for non-stimulant medications for ADHD, with a particular focus on atomoxetine and alpha agonists guanfacine and clonidine.
Conclusion: Non-stimulants are for the most part well tolerated but monitoring for cardiac and sleep difficulty is warranted.
Keywords: Mental health, children and adolescents, psychopharmacology, ADHD, attention deficit disorder, atomoxetine, alpha agonists.
Graphical Abstract
Current Psychopharmacology
Title:Adverse Effects of Non-Stimulant ADHD Drugs: Atomoxetine, Alpha-Agonists
Volume: 7
Author(s): Myrtha Gregoire-Bottex*Katherine Soe
Affiliation:
- Department of Pediatrics and Adolescent Medicine, Western Michigan University, Homer Stryker M.D. School of Medicine, 1000 Oakland Drive, Kalamazoo, Michigan, MI,United States
Keywords: Mental health, children and adolescents, psychopharmacology, ADHD, attention deficit disorder, atomoxetine, alpha agonists.
Abstract: Background: Attention-deficit/hyperactivity disorder (ADHD) is a widespread diagnosis that affects many children and adolescents’ ability to function and succeed in academics, socially, or other situations. Non-stimulant medications have become widely utilized in this population, especially in stimulant-resistant individuals, whether due to poor efficacy or intolerance of side effects. However, these, too, harbor their own side effect profiles, including cardiovascular and sleep or energy level disturbances.
Objectives: We review the literature in discussion of the presentation and management of these adverse events for non-stimulant medications for ADHD, with a particular focus on atomoxetine and alpha agonists guanfacine and clonidine.
Conclusion: Non-stimulants are for the most part well tolerated but monitoring for cardiac and sleep difficulty is warranted.
Export Options
About this article
Cite this article as:
Gregoire-Bottex Myrtha *, Soe Katherine , Adverse Effects of Non-Stimulant ADHD Drugs: Atomoxetine, Alpha-Agonists, Current Psychopharmacology 2018; 7 (1) . https://dx.doi.org/10.2174/2211556007666180328150248
DOI https://dx.doi.org/10.2174/2211556007666180328150248 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology G-Protein Coupled Receptor Resensitization - Appreciating the Balancing Act of Receptor Function
Current Molecular Pharmacology Navigating Alzheimer’s Disease via Chronic Stress: The Role of Glucocorticoids
Current Drug Targets From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings
Current Neuropharmacology Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases
Current Aging Science Small Molecules and Alzheimer’s Disease: Misfolding, Metabolism and Imaging
Current Alzheimer Research Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings
Current Pharmaceutical Design Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens
Current Drug Metabolism Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Current Neuropharmacology Nanocarbon Materials for Photodynamic Therapy and Photothermal Therapy
Pharmaceutical Nanotechnology Old Weapons for New Wars: Bioactive Molecules From Cnidarian Internal Defense Systems
Central Nervous System Agents in Medicinal Chemistry Expectancy and the Treatment of Depression: A Review of Experimental Methodology and Effects on Patient Outcome
Current Psychiatry Reviews Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target
Current Medicinal Chemistry Editorial (Thematic Issue: New Approaches to the Treatment of Alzheimer's Disease)
Current Topics in Medicinal Chemistry Metabolomics and Its Practical Value in Pharmaceutical Industry
Current Drug Metabolism Anti-inflammatory, Analgesic and Anti-ulcerogenic Activities of Novel bis-thiadiazoles, bis-thiazoles and bis-formazanes
Medicinal Chemistry